Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech Inc. (NYSE American: AIM) announced an update on its Phase 2a Human Challenge Trial for its drug Ampligen, targeting intranasal prophylactic therapy against human rhinovirus (HRV-16) and influenza A virus (H3N2). The study protocol was submitted to the Oxford Research Ethics Committee, with a review meeting scheduled for September 24, 2021. The trial plans to enroll 64 participants in a double-blind setup to evaluate Ampligen's efficacy. A successful outcome may position Ampligen as a preventative treatment for various respiratory viruses. AIM is collaborating with hVIVO to finalize a Clinical Trial Agreement.
AIM ImmunoTech Inc. (NYSE American: AIM) has submitted a Pre-Investigational New Drug application to the FDA for a Phase 2 clinical study of Ampligen, aimed at treating Post-COVID-19 Cognitive Dysfunction (PCCD). This randomized, double-blind, placebo-controlled study will involve 80 participants receiving Ampligen or placebo for 12 weeks. The preliminary IND filing is deemed a major milestone and could potentially alleviate the debilitating effects of PCCD, which impacts cognitive function and daily activities. AIM also filed a provisional patent for Ampligen as both intravenous and intranasal therapy for PCCD.
AIM ImmunoTech Inc. announced significant updates regarding its drug Ampligen as a treatment for Post-COVID-19 Cognitive Dysfunction (PCCD). In the ongoing AMP-511 Early Access Program, patients have reported noticeable improvements in cognitive function. A new provisional patent application has been filed for Ampligen as both intranasal and intravenous therapies for PCCD, expanding AIM's patent portfolio for COVID-19 therapeutics. The CEO emphasized the urgent need for effective treatments for COVID-19 and its long-term effects.
On August 17, 2021, AIM ImmunoTech Inc. (NYSE American: AIM) announced its financial results for Q2 2021. The company reported cash and equivalents of $57.3 million, up from $54.4 million at year-end 2020. R&D expenses decreased to $1.3 million, while G&A expenses rose to $2.1 million, leading to a net loss of $5.9 million. AIM is focusing on expedited clinical trials for drug approval, with promising data from Ampligen studies in pancreatic cancer. Additionally, AIM is advancing COVID-19 trials, including a Phase 2a human challenge trial expected in Q4 2021.
AIM ImmunoTech Inc. announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc. This organization represents over 6,700 establishments in Florida's life sciences sector, employing nearly 94,000 individuals. Equels expressed pride in contributing to the potential development of therapies for serious diseases, including cancers and COVID-19. This appointment may enhance AIM's influence within Florida's vibrant life sciences industry.
AIM ImmunoTech has announced a Phase 2a Human Challenge Trial to evaluate Ampligen as an intranasal antiviral therapy against human rhinovirus and influenza. Sponsored by hVIVO, this trial aims to assess Ampligen's effectiveness, with a focus on its potential to serve as a prophylaxis against future respiratory viruses, including SARS-CoV-2. Following the completion of a successful Phase 1 study, which reported no severe adverse events in 40 subjects, the Phase 2a trial is expected to begin in Q4 2021, potentially accelerating the drug's development process.
On July 6, 2021, AIM ImmunoTech Inc. (NYSE American: AIM) announced an upcoming investor update webcast scheduled for July 14, 2021, at 11:00 a.m. Eastern Time. The session will cover recent achievements and future milestones. Investors are encouraged to submit their questions via email before the call. The webcast can be accessed through the company’s website, and a replay will be available until July 14, 2022. AIM ImmunoTech is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech Inc. has announced the completion of treatment in its Phase 1 clinical study of Ampligen as a potential intranasal therapy for respiratory viruses. A total of 40 healthy subjects participated, with no Severe Adverse Events reported. With positive results, the company is now planning a Phase 2 study to evaluate Ampligen's efficacy as a broad-spectrum respiratory virus prophylaxis, targeting various viruses including influenza and coronaviruses. This development aims to provide preventive therapy for vulnerable populations, pending further testing.
AIM ImmunoTech Inc. has received a patent in the Netherlands for Ampligen, recognizing its potential as a combination therapy with checkpoint blockade inhibitors. The drug's efficacy in treating cancer patients infected with SARS-CoV-2 has been highlighted in a peer-reviewed study. Research suggests Ampligen may activate immune responses against cancers and reduce COVID-19 severity. The patent, effective until December 2039, marks significant progress in AIM's drug development efforts.
AIM ImmunoTech Inc. has announced a two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited to develop Ampligen as a potential inhalation therapy for COVID-19 and other respiratory diseases. Preliminary testing showed that Ampligen could reduce SARS-CoV-2 infectious viral yields by 90% at achievable dosages. AIM plans to begin a Phase 1/2 clinical study alongside the development of Smoore's inhalation device, focusing on safety and efficacy before year-end.